Literature DB >> 35142107

New developments in the biology of fibroblast growth factors.

David M Ornitz1, Nobuyuki Itoh2.   

Abstract

The fibroblast growth factor (FGF) family is composed of 18 secreted signaling proteins consisting of canonical FGFs and endocrine FGFs that activate four receptor tyrosine kinases (FGFRs 1-4) and four intracellular proteins (intracellular FGFs or iFGFs) that primarily function to regulate the activity of voltage-gated sodium channels and other molecules. The canonical FGFs, endocrine FGFs, and iFGFs have been reviewed extensively by us and others. In this review, we briefly summarize past reviews and then focus on new developments in the FGF field since our last review in 2015. Some of the highlights in the past 6 years include the use of optogenetic tools, viral vectors, and inducible transgenes to experimentally modulate FGF signaling, the clinical use of small molecule FGFR inhibitors, an expanded understanding of endocrine FGF signaling, functions for FGF signaling in stem cell pluripotency and differentiation, roles for FGF signaling in tissue homeostasis and regeneration, a continuing elaboration of mechanisms of FGF signaling in development, and an expanding appreciation of roles for FGF signaling in neuropsychiatric diseases. This article is categorized under: Cardiovascular Diseases > Molecular and Cellular Physiology Neurological Diseases > Molecular and Cellular Physiology Congenital Diseases > Stem Cells and Development Cancer > Stem Cells and Development.
© 2022 Wiley Periodicals LLC.

Entities:  

Keywords:  fibroblast growth factors; organogenesis; receptor tyrosine kinase; regeneration; tyrosine kinase inhibitors

Mesh:

Substances:

Year:  2022        PMID: 35142107     DOI: 10.1002/wsbm.1549

Source DB:  PubMed          Journal:  WIREs Mech Dis        ISSN: 2692-9368


  5 in total

1.  Fibroblast growth factor-9 expression in airway epithelial cells amplifies the type I interferon response and alters influenza A virus pathogenesis.

Authors:  Bradley E Hiller; Yongjun Yin; Yi-Chieh Perng; Ítalo de Araujo Castro; Lindsey E Fox; Marissa C Locke; Kristen J Monte; Carolina B López; David M Ornitz; Deborah J Lenschow
Journal:  PLoS Pathog       Date:  2022-06-08       Impact factor: 7.464

Review 2.  Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis.

Authors:  Hongbo Ma; Shengming Liu; Shanrui Li; Yong Xia
Journal:  Front Pharmacol       Date:  2022-06-03       Impact factor: 5.988

Review 3.  Beyond targeting amplified MDM2 and CDK4 in well differentiated and dedifferentiated liposarcomas: From promise and clinical applications towards identification of progression drivers.

Authors:  Giuliana Cassinelli; Sandro Pasquali; Cinzia Lanzi
Journal:  Front Oncol       Date:  2022-09-02       Impact factor: 5.738

4.  A dominant negative mutation uncovers cooperative control of caudal Wolffian duct development by Sprouty genes.

Authors:  Gisela Altés; Marta Vaquero; Sara Cuesta; Carlos Anerillas; Anna Macià; Carme Espinet; Joan Ribera; Saverio Bellusci; Ophir D Klein; Andree Yeramian; Xavi Dolcet; Joaquim Egea; Mario Encinas
Journal:  Cell Mol Life Sci       Date:  2022-09-13       Impact factor: 9.207

5.  Fibroblast growth factor receptor signaling in cardiomyocytes is protective in the acute phase following ischemia-reperfusion injury.

Authors:  Dzmitry Matsiukevich; Stacey L House; Carla Weinheimer; Attila Kovacs; David M Ornitz
Journal:  Front Cardiovasc Med       Date:  2022-09-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.